Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 401

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies

Open access
Steichen, Jon M., Kulp, Daniel W., Tokatlian, Talar, Escolano, Amelia, Dosenovic, Pia, Stanfield, Robyn L., McCoy, Laura E., Ozorowski, Gabriel, Hu, Xiaozhen, Kalyuzhniy, Oleksandr, Briney, Bryan, Schiffner, Torben, Garces, Fernando, Freund, Natalia T., Gitlin, Alexander D., Menis, Sergey, Georgeson, Erik, Kubitz, Michael, Adachi, Yumiko, Jones, Meaghan, Mutafyan, Andrew A., Yun, Dong Soo, Mayer, Christian T., Ward, Andrew B., Burton, Dennis R., Wilson, Ian A., Irvine, Darrell J., Nussenzweig, Michel C., Schief, William R.·2016·Immunity

Abstract

Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) trimer are the most common bnAbs induced during infection, making them promising leads for vaccine design. Wild-type Env glycoproteins lack detectable affinity for supersite-bnAb germline precursors and are therefore unsuitable immunogens to prime supersite-bnAb responses. We employed mammalian cell surface display to design stabilized Env trimers with affinity for germline-reverted precursors of PGT121-class supersite bnAbs. The trimers maintained native-like antigenicity and structure, activated PGT121 inferred-germline B cells ex vivo when multimerized on liposomes, and primed PGT121-like responses in PGT121 inferred-germline knockin mice. Design intermediates have levels of epitope modification between wild-type and germline-targeting trimers; their mutation gradient suggests sequential immunization to induce bnAbs, in which the germline-targeting prime is followed by progressively less-mutated design intermediates and, lastly, with native trimers. The vaccine design strategies described could be utilized to target other epitopes on HIV or other pathogens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2016.08.016

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 401

Metadata

Authors
Steichen, J. M., Kulp, D. W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R. L., McCoy, L. E., Ozorowski, G., Hu, X., Kalyuzhniy, O., Briney, B., Schiffner, T., Garces, F., Freund, N. T., Gitlin, A. D., Menis, S., Georgeson, E., Kubitz, M., Adachi, Y., Jones, M., Mutafyan, A. A., Yun, D. S., Mayer, C. T., Ward, A. B., Burton, D. R., Wilson, I. A., Irvine, D. J., Nussenzweig, M. C., & Schief, W. R.
Venue
Immunity
Publisher
Elsevier BV
Published
2016-09
Volume
45
Issue
3
Pages
483-496
ISSN
1074-7613 (ISSN-L)
OpenAlex
W2520562417
Cited by
401
References
60
FWCI
29.67
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. https://app.cochat.ai/papers/10.1016/j.immuni.2016.08.016
The paper
Steichen, J. M., Kulp, D. W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R. L., McCoy, L. E., Ozorowski, G., Hu, X., Kalyuzhniy, O., Briney, B., Schiffner, T., Garces, F., Freund, N. T., Gitlin, A. D., Menis, S., Georgeson, E., Kubitz, M., Adachi, Y., . . . Schief, W. R. (2016). HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity. https://doi.org/10.1016/j.immuni.2016.08.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.